Evaluation of 18F‐FDG PET/CT as an early imaging biomarker for response monitoring after radiochemotherapy using cetuximab in head and heck squamous cell carcinoma

Background To determine whether 18 F‐PET/CT is able to identify treatment response as early as 1 week after the end of chemoradiotherapy, whether 18 F‐PET/CT can identify prognostic markers concerning progression free survival and can identify patients who need additional consolidation therapy. Methods A total of 54 patients with head and neck cancer were prospectively enrolled in this single‐center, randomized study from 03/2012‐04/2015....